Stocks in Play

BioVaxys Technology Corp

09:58 AM EST - BioVaxys Technology Corp : Announces positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S") along with neoadjuvant hormone therapy in women with hormone receptor positive HER2 negative (HR+HER2-) stage II-III breast cancer. BioVaxys Technology Corp shares C.BIOV are trading up $0.02 at $0.24.

Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=7298889010506122